Aktis Oncology (NASDAQ:AKTS) Shares Up 7.2% – Still a Buy?

Shares of Aktis Oncology (NASDAQ:AKTS) rose 7.2% during trading on Monday . The company traded as high as $20.59 and last traded at $20.3630. Approximately 226,889 shares changed hands during mid-day trading, a decline of 13% from the average daily volume of 260,851 shares. The stock had previously closed at $18.99.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AKTS. HC Wainwright initiated coverage on shares of Aktis Oncology in a research note on Monday, March 9th. They set a “buy” rating and a $30.00 price target on the stock. Leerink Partners initiated coverage on shares of Aktis Oncology in a report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 price objective on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. JPMorgan Chase & Co. assumed coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set an “overweight” rating and a $30.00 price target for the company. Finally, TD Cowen initiated coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Five research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $31.25.

Aktis Oncology Stock Performance

The company’s fifty day simple moving average is $19.71.

Insider Buying and Selling

In other Aktis Oncology news, major shareholder Ansbert Gadicke purchased 1,112,777 shares of the stock in a transaction on Monday, January 12th. The shares were bought at an average cost of $18.00 per share, with a total value of $20,029,986.00. Following the completion of the acquisition, the insider owned 10,260,064 shares in the company, valued at $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the purchase, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 6,117,776 shares of company stock valued at $110,119,968 in the last 90 days.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.